Valuation: Beijing Bohui Innovation Biotechnology Group Co., Ltd.

Market Cap 3.78B 567M 509M 470M 426M 797M 53.87B 806M 5.64B 2.24B 28.24B 2.13B 2.08B 89.54B P/E 2024
506x
P/E 2025 -55.7x
Enterprise Value 4.79B 718M 644M 595M 539M 1.01B 68.16B 1.02B 7.13B 2.83B 35.73B 2.69B 2.64B 113B EV / Sales 2024
6.63x
EV / Sales 2025 7.43x
Free-Float
37.78%
Yield 2024 *
-
Yield 2025 -
08-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
06-25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Announces Changes to Its Board CI
04-27 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-24 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-24 Beijing Bohui Innovation Biotechnology Group Co., Ltd. announced that it expects to receive CNY 300 million in funding CI
01-14 Bohui Innovation Biotechnology Gets Clinical Trial Approval for Anti-Rabies Human Rabies MT
11-12 Bohui Innovation Biotechnology JV Gets Clinical Trial Approval for Hib Vaccine MT
29/10/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
27/08/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
02/06/25 Bohui Innovation Biotechnology Secures Approval for Virus Detection Kit MT
28/04/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25/04/25 Beijing Bohui Innovation Biotechnology Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
21/02/25 Beijing Bohui Innovation Biotechnology Group Subsidiary Gains Clinical Trial Approval for Flu Vaccine MT
1 day-3.54%
1 week-3.34%
Current month-11.47%
1 month-10.44%
3 months-0.22%
6 months-16.73%
Current year-26.16%
1 week 4.39
Extreme 4.39
4.86
1 month 4.39
Extreme 4.39
5.34
Current year 4.06
Extreme 4.06
8.17
1 year 4.06
Extreme 4.06
8.63
3 years 3.43
Extreme 3.43
8.63
5 years 3.43
Extreme 3.43
12.28
10 years 3.43
Extreme 3.43
23.8
Manager TitleAgeSince
Chief Executive Officer 56 17/03/2020
Director of Finance/CFO 42 29/06/2020
Corporate Officer/Principal 48 17/03/2020
Director TitleAgeSince
Chairman 58 19/05/2014
Chairman 48 01/06/2022
Director/Board Member 56 29/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
02/11/21 Sell

Executive/Senior Manager

268,300 0.0364%
15/09/21 Sell

Executive/Senior Manager

50,000 0.0068%
26/01/21 Buy

Chairman

29,000 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-3.54%-3.34%-18.77%-23.60% 567M
+0.22%-0.14%+55.12%+128.82% 1,143B
+0.91%+3.61%+41.21%+84.57% 647B
-0.12%-0.93%+25.59%+106.14% 506B
+0.63%+2.33%+49.21%+67.82% 384B
+0.86%-4.37%+61.16%+37.93% 350B
+1.02%+1.80%+24.84%+53.75% 293B
-0.25%+1.62%+2.20%+26.65% 265B
+0.75%+2.05%+53.85%+71.25% 242B
+0.25%+1.64%+32.05%+107.62% 197B
Average +0.07%+0.53%+32.65%+66.10% 402.81B
Weighted average by Cap. +0.44%+0.71%+42.24%+88.44%

Financials

2024 2025
Net sales 852M 128M 115M 106M 95.98M 179M 12.13B 182M 1.27B 504M 6.36B 479M 469M 20.16B 825M 124M 111M 102M 92.92M 174M 11.74B 176M 1.23B 488M 6.16B 464M 454M 19.52B
Net income 9.25M 1.39M 1.24M 1.15M 1.04M 1.95M 132M 1.97M 13.78M 5.47M 69.03M 5.2M 5.09M 219M -91.92M -13.78M -12.37M -11.42M -10.36M -19.36M -1.31B -19.6M -137M -54.39M -686M -51.74M -50.63M -2.18B
Net Debt 974M 146M 131M 121M 110M 205M 13.87B 208M 1.45B 576M 7.27B 548M 536M 23.06B 1B 150M 135M 125M 113M 211M 14.29B 214M 1.49B 594M 7.49B 565M 553M 23.76B
Projected Income Statement - Annual - Beijing Bohui Innovation Biotechnology Group Co., Ltd.
Logo Beijing Bohui Innovation Biotechnology Group Co., Ltd.
Beijing Bohui Innovation Biotechnology Group Co Ltd, formerly Beijing Bohui Innovation Biotechnology Co Ltd is a China-based company mainly engaged in testing and biological products. The testing business products are divided into testing instruments and testing reagents, including human papillomavirus (HPV) testing products, trace element testing products, mass spectrometry related testing products, and others. The biological products mainly cover three categories: albumin, immunoglobulin and human coagulation factors, including human serum albumin, human immunoglobulin, intravenous human immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, and others. The Company mainly operates its business in the domestic market.
Employees
2,170
Date Price Change Volume
27/10/26 CN¥4.630 -3.54% 8,692,488
26/10/26 CN¥4.800 +2.56% 7,297,500
23/10/26 CN¥4.680 +1.30% 8,351,133
22/10/26 CN¥4.620 -2.53% 6,090,514
21/10/26 CN¥4.740 -1.04% 5,506,000
  1. Stock Market
  2. Stocks
  3. 300318 Stock